- Home
- SRAD vs ALKS Comparison
SRAD vs ALKS Comparison
Compare SRAD & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRAD
- ALKS
- Stock Information
- Founded
- SRAD 2001
- ALKS 1987
- Country
- SRAD Switzerland
- ALKS Ireland
- Employees
- SRAD N/A
- ALKS N/A
- Industry
- SRAD Computer Software: Programming Data Processing
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- SRAD Technology
- ALKS Health Care
- Exchange
- SRAD Nasdaq
- ALKS Nasdaq
- Market Cap
- SRAD 5.2B
- ALKS 4.4B
- IPO Year
- SRAD 2021
- ALKS 1991
- Fundamental
- Price
- SRAD $16.94
- ALKS $28.17
- Analyst Decision
- SRAD Strong Buy
- ALKS Buy
- Analyst Count
- SRAD 9
- ALKS 12
- Target Price
- SRAD $15.56
- ALKS $35.42
- AVG Volume (30 Days)
- SRAD 861.9K
- ALKS 1.9M
- Earning Date
- SRAD 11-07-2024
- ALKS 10-24-2024
- Dividend Yield
- SRAD N/A
- ALKS N/A
- EPS Growth
- SRAD N/A
- ALKS 55.25
- EPS
- SRAD 0.20
- ALKS 1.97
- Revenue
- SRAD $1,173,401,739.00
- ALKS $1,505,121,000.00
- Revenue This Year
- SRAD $25.68
- ALKS N/A
- Revenue Next Year
- SRAD $13.33
- ALKS N/A
- P/E Ratio
- SRAD $83.14
- ALKS $12.40
- Revenue Growth
- SRAD 26.55
- ALKS N/A
- 52 Week Low
- SRAD $9.17
- ALKS $22.22
- 52 Week High
- SRAD $17.52
- ALKS $32.88
- Technical
- Relative Strength Index (RSI)
- SRAD 80.20
- ALKS 49.75
- Support Level
- SRAD $12.26
- ALKS $28.10
- Resistance Level
- SRAD $17.52
- ALKS $30.30
- Average True Range (ATR)
- SRAD 0.60
- ALKS 0.84
- MACD
- SRAD 0.46
- ALKS 0.11
- Stochastic Oscillator
- SRAD 88.97
- ALKS 50.32
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.